Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Urodynamic Mechanisms Underlying Overactive Bladder Symptoms in Patients With Parkinson Disease.

Vurture G, Peyronnet B, Palma JA, Sussman RD, Malacarne DR, Feigin A, Palmerola R, Rosenblum N, Frucht S, Kaufmann H, Nitti VW, Brucker BM.

Int Neurourol J. 2019 Sep;23(3):211-218. doi: 10.5213/inj.1938086.043. Epub 2019 Sep 30.

2.

High prevalence of attention-deficit/hyperactivity disorder in adolescents with severe obesity seeking bariatric surgery.

Leib S, Gilon Mann T, Stein D, Vusiker I, Tokatly Latzer I, Ben-Ami M, Feigin A, Dubnov-Raz G.

Acta Paediatr. 2019 Sep 28. doi: 10.1111/apa.15039. [Epub ahead of print]

PMID:
31562776
3.

H2O2 photoproduction inside H2O and H2O:O2 ices at 20-140 K.

Kulikov MY, Feigin AM, Schrems O.

Sci Rep. 2019 Aug 6;9(1):11375. doi: 10.1038/s41598-019-47915-w.

4.

Bayesian Data Analysis for Revealing Causes of the Middle Pleistocene Transition.

Mukhin D, Gavrilov A, Loskutov E, Kurths J, Feigin A.

Sci Rep. 2019 May 13;9(1):7328. doi: 10.1038/s41598-019-43867-3.

5.

Tele-monitored tDCS rehabilitation: feasibility, challenges and future perspectives in Parkinson's disease.

Cucca A, Sharma K, Agarwal S, Feigin AS, Biagioni MC.

J Neuroeng Rehabil. 2019 Jan 31;16(1):20. doi: 10.1186/s12984-019-0481-4. Review.

6.

Gene therapy reduces Parkinson's disease symptoms by reorganizing functional brain connectivity.

Niethammer M, Tang CC, Vo A, Nguyen N, Spetsieris P, Dhawan V, Ma Y, Small M, Feigin A, During MJ, Kaplitt MG, Eidelberg D.

Sci Transl Med. 2018 Nov 28;10(469). pii: eaau0713. doi: 10.1126/scitranslmed.aau0713.

PMID:
30487248
7.

Visuospatial exploration and art therapy intervention in patients with Parkinson's disease: an exploratory therapeutic protocol.

Cucca A, Acosta I, Berberian M, Lemen AC, Rizzo JR, Ghilardi MF, Quartarone A, Feigin AS, Di Rocco A, Biagioni MC.

Complement Ther Med. 2018 Oct;40:70-76. doi: 10.1016/j.ctim.2018.07.011. Epub 2018 Jul 27.

8.

Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort.

Peyronnet B, Vurture G, Palma JA, Malacarne DR, Feigin A, Sussman RD, Biagioni MC, Palmerola R, Gilbert R, Rosenblum N, Frucht S, Kaufmann H, Nitti VW, Brucker BM.

Parkinsonism Relat Disord. 2018 Dec;57:22-26. doi: 10.1016/j.parkreldis.2018.07.005. Epub 2018 Jul 20.

PMID:
30037689
9.

Outcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's disease.

Vurture G, Peyronnet B, Feigin A, Biagioni MC, Gilbert R, Rosenblum N, Frucht S, Di Rocco A, Nitti VW, Brucker BM.

Neurourol Urodyn. 2018 Nov;37(8):2669-2677. doi: 10.1002/nau.23717. Epub 2018 May 16.

PMID:
29767449
10.

Biomarkers for atypical Parkinsonism: Some progress, but much work remains.

Feigin A, Siderowf A.

Parkinsonism Relat Disord. 2018 Mar;48:1-2. doi: 10.1016/j.parkreldis.2018.02.025. No abstract available.

PMID:
29478511
11.

Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesia.

Jourdain VA, Schindlbeck KA, Tang CC, Niethammer M, Choi YY, Markowitz D, Nazem A, Nardi D, Carras N, Feigin A, Ma Y, Peng S, Dhawan V, Eidelberg D.

JCI Insight. 2017 Oct 19;2(20). pii: 96411. doi: 10.1172/jci.insight.96411.

12.

Preface.

Feigin AS, Anderson KE.

Handb Clin Neurol. 2017;144:ix. doi: 10.1016/B978-0-12-801893-4.09986-7. No abstract available.

PMID:
28947130
13.

National randomized controlled trial of virtual house calls for Parkinson disease.

Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W; Connect.Parkinson Investigators.

Neurology. 2017 Sep 12;89(11):1152-1161. doi: 10.1212/WNL.0000000000004357. Epub 2017 Aug 16.

14.

Restless legs syndrome: Losing sleep over the placebo response.

Feigin A.

Neurology. 2017 Jun 6;88(23):2160-2161. doi: 10.1212/WNL.0000000000004018. Epub 2017 May 10. No abstract available.

PMID:
28490652
15.

Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson's disease.

Niethammer M, Tang CC, LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Sapan CV, Eidelberg D, During MJ, Kaplitt MG, Feigin A.

JCI Insight. 2017 Apr 6;2(7):e90133. doi: 10.1172/jci.insight.90133.

16.

Method for reconstructing nonlinear modes with adaptive structure from multidimensional data.

Gavrilov A, Mukhin D, Loskutov E, Volodin E, Feigin A, Kurths J.

Chaos. 2016 Dec;26(12):123101. doi: 10.1063/1.4968852.

PMID:
28039974
17.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

18.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

19.

Longitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's Disease.

Holtbernd F, Tang CC, Feigin A, Dhawan V, Ghilardi MF, Paulsen JS, Guttman M, Eidelberg D.

PLoS One. 2016 May 18;11(5):e0154742. doi: 10.1371/journal.pone.0154742. eCollection 2016.

20.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

PMID:
26990766
21.

National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers.

Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W.

Telemed J E Health. 2016 Jul;22(7):590-8. doi: 10.1089/tmj.2015.0191. Epub 2016 Feb 17.

22.

Bariatric Surgery Improves Sexual Function in Obese Patients.

Goitein D, Zendel A, Segev L, Feigin A, Zippel D.

Isr Med Assoc J. 2015 Oct;17(10):616-9.

23.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
24.

Principal nonlinear dynamical modes of climate variability.

Mukhin D, Gavrilov A, Feigin A, Loskutov E, Kurths J.

Sci Rep. 2015 Oct 22;5:15510. doi: 10.1038/srep15510.

25.

Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study.

Tripathi M, Tang CC, Feigin A, De Lucia I, Nazem A, Dhawan V, Eidelberg D.

J Nucl Med. 2016 Jan;57(1):60-6. doi: 10.2967/jnumed.115.161992. Epub 2015 Oct 8.

26.

A disease-specific metabolic brain network associated with corticobasal degeneration.

Niethammer M, Tang CC, Feigin A, Allen PJ, Heinen L, Hellwig S, Amtage F, Hanspal E, Vonsattel JP, Poston KL, Meyer PT, Leenders KL, Eidelberg D.

Brain. 2014 Nov;137(Pt 11):3036-46. doi: 10.1093/brain/awu256. Epub 2014 Sep 9.

27.

Network modulation following sham surgery in Parkinson's disease.

Ko JH, Feigin A, Mattis PJ, Tang CC, Ma Y, Dhawan V, During MJ, Kaplitt MG, Eidelberg D.

J Clin Invest. 2014 Aug;124(8):3656-66. doi: 10.1172/JCI75073. Epub 2014 Jul 18.

28.

A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.

JAMA Neurol. 2014 May;71(5):543-52. doi: 10.1001/jamaneurol.2014.131.

PMID:
24664227
29.

Abnormal metabolic network activity in REM sleep behavior disorder.

Holtbernd F, Gagnon JF, Postuma RB, Ma Y, Tang CC, Feigin A, Dhawan V, Vendette M, Soucy JP, Eidelberg D, Montplaisir J.

Neurology. 2014 Feb 18;82(7):620-7. doi: 10.1212/WNL.0000000000000130. Epub 2014 Jan 22.

30.

Expanding the genetics of huntingtonism.

Feigin A, Talbot K.

Neurology. 2014 Jan 28;82(4):286-7. doi: 10.1212/WNL.0000000000000067. Epub 2013 Dec 20. No abstract available.

PMID:
24363136
31.

Gene-based therapies in Parkinson's disease.

Allen PJ, Feigin A.

Neurotherapeutics. 2014 Jan;11(1):60-7. doi: 10.1007/s13311-013-0233-2. Review.

32.

Metabolic network as a progression biomarker of premanifest Huntington's disease.

Tang CC, Feigin A, Ma Y, Habeck C, Paulsen JS, Leenders KL, Teune LK, van Oostrom JC, Guttman M, Dhawan V, Eidelberg D.

J Clin Invest. 2013 Sep;123(9):4076-88. doi: 10.1172/JCI69411. Epub 2013 Aug 29.

33.

Characterization of disease-related covariance topographies with SSMPCA toolbox: effects of spatial normalization and PET scanners.

Peng S, Ma Y, Spetsieris PG, Mattis P, Feigin A, Dhawan V, Eidelberg D.

Hum Brain Mapp. 2014 May;35(5):1801-14. doi: 10.1002/hbm.22295. Epub 2013 May 14.

34.

Redefining the genetic risk for Huntington disease.

Feigin A.

Neurology. 2013 May 28;80(22):2004-5. doi: 10.1212/WNL.0b013e318294b49b. Epub 2013 Apr 26. No abstract available.

PMID:
23624565
35.

Increases in newly acquired HIV infections in Victoria, Australia: epidemiological evidence of successful prevention?

Feigin A, El-Hayek C, Hellard M, Pedrana A, Donnan E, Fairley C, Tee BK, Stoové M.

Sex Health. 2013 May;10(2):166-70. doi: 10.1071/SH12064.

PMID:
23597592
36.

Deep brain stimulation for the treatment of tremor and ataxia associated with abetalipoproteinemia.

Mammis A, Pourfar M, Feigin A, Mogilner AY.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-45-228-1. doi: 10.7916/D8542M96. Epub 2012 Jul 2.

37.

Structure, Energy, and Vibrational Frequencies of Oxygen Allotropes On (n ≤ 6) in the Covalently Bound and van der Waals Forms: Ab Initio Study at the CCSD(T) Level.

Gadzhiev OB, Ignatov SK, Kulikov MY, Feigin AM, Razuvaev AG, Sennikov PG, Schrems O.

J Chem Theory Comput. 2013 Jan 8;9(1):247-62. doi: 10.1021/ct3006584. Epub 2012 Nov 27.

PMID:
26589027
38.

Monitoring Huntington's disease progression through preclinical and early stages.

Tang C, Feigin A.

Neurodegener Dis Manag. 2012 Aug 1;2(4):421-435.

39.

Random dynamical models from time series.

Molkov YI, Loskutov EM, Mukhin DN, Feigin AM.

Phys Rev E Stat Nonlin Soft Matter Phys. 2012 Mar;85(3 Pt 2):036216. Epub 2012 Mar 26.

PMID:
22587170
40.

Functional neuroimaging in Parkinson's disease.

Niethammer M, Feigin A, Eidelberg D.

Cold Spring Harb Perspect Med. 2012 May;2(5):a009274. doi: 10.1101/cshperspect.a009274. Review.

41.

Pridopidine in treatment of Huntington's disease: beyond chorea?

Feigin A.

Lancet Neurol. 2011 Dec;10(12):1036-7. doi: 10.1016/S1474-4422(11)70247-2. Epub 2011 Nov 7. No abstract available.

PMID:
22071278
42.

Prognosis of qualitative system behavior by noisy, nonstationary, chaotic time series.

Molkov YI, Mukhin DN, Loskutov EM, Timushev RI, Feigin AM.

Phys Rev E Stat Nonlin Soft Matter Phys. 2011 Sep;84(3 Pt 2):036215. Epub 2011 Sep 23.

PMID:
22060483
43.

Basal ganglia and kinematics modulation: insights from Parkinson's and Huntington's diseases.

Moisello C, Perfetti B, Marinelli L, Sanguineti V, Bove M, Feigin A, Di Rocco A, Eidelberg D, Ghilardi MF.

Parkinsonism Relat Disord. 2011 Sep;17(8):642-4. doi: 10.1016/j.parkreldis.2011.06.021. Epub 2011 Jul 20.

44.

The impact of khat use on East African communities in Melbourne: a preliminary investigation.

Feigin A, Higgs P, Hellard M, Dietze P.

Drug Alcohol Rev. 2012 May;31(3):288-93. doi: 10.1111/j.1465-3362.2011.00312.x. Epub 2011 Apr 5.

PMID:
21463373
45.

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial.

LeWitt PA, Rezai AR, Leehey MA, Ojemann SG, Flaherty AW, Eskandar EN, Kostyk SK, Thomas K, Sarkar A, Siddiqui MS, Tatter SB, Schwalb JM, Poston KL, Henderson JM, Kurlan RM, Richard IH, Van Meter L, Sapan CV, During MJ, Kaplitt MG, Feigin A.

Lancet Neurol. 2011 Apr;10(4):309-19. doi: 10.1016/S1474-4422(11)70039-4.

PMID:
21419704
46.

Laparoscopic sleeve gastrectomy as a revisional option after gastric band failure.

Goitein D, Feigin A, Segal-Lieberman G, Goitein O, Papa MZ, Zippel D.

Surg Endosc. 2011 Aug;25(8):2626-30. doi: 10.1007/s00464-011-1615-3. Epub 2011 Mar 17.

PMID:
21416182
47.

Abnormal metabolic brain networks in Tourette syndrome.

Pourfar M, Feigin A, Tang CC, Carbon-Correll M, Bussa M, Budman C, Dhawan V, Eidelberg D.

Neurology. 2011 Mar 15;76(11):944-52. doi: 10.1212/WNL.0b013e3182104106. Epub 2011 Feb 9.

48.

Further research required to determine link between khat consumption and driver impairment.

Feigin A, Higgs P, Hellard M, Dietze P.

Bull World Health Organ. 2010 Jun;88(6):480. doi: 10.2471/BLT.10.077693. No abstract available.

49.

A randomized, placebo-controlled trial of latrepirdine in Huntington disease.

Kieburtz K, McDermott MP, Voss TS, Corey-Bloom J, Deuel LM, Dorsey ER, Factor S, Geschwind MD, Hodgeman K, Kayson E, Noonberg S, Pourfar M, Rabinowitz K, Ravina B, Sanchez-Ramos J, Seely L, Walker F, Feigin A; Huntington Disease Study Group DIMOND Investigators.

Arch Neurol. 2010 Feb;67(2):154-60. doi: 10.1001/archneurol.2009.334. Erratum in: Arch Neurol. 2010 Apr;67(4):492. Dimebon in Subjects With Huntington Disease (DIMOND)Investigators of the Huntington Study Group [corrected to Huntington Disease Study Group DIMOND Investigators].

50.

Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis.

Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, Dhawan V, Lesser M, Vonsattel JP, Fahn S, Eidelberg D.

Lancet Neurol. 2010 Feb;9(2):149-58. doi: 10.1016/S1474-4422(10)70002-8. Epub 2010 Jan 8.

Supplemental Content

Loading ...
Support Center